Opioid blocker shows promise in understanding low testosterone
NCT ID NCT04975334
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study looked at how a drug that blocks opioids (naloxone) affects hormone signals in men with hypogonadotropic hypogonadism, a condition where the brain doesn't tell the testes to make enough testosterone. Twenty-three men participated, and researchers measured changes in a key hormone called luteinizing hormone. The goal was to better understand the brain's role in this condition, not to provide a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOGONADOTROPIC HYPOGONADISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.